Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 431-230-3 | CAS number: 202483-62-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Toxicity to reproduction
Administrative data
- Endpoint:
- screening for reproductive / developmental toxicity
- Remarks:
- based on test type (migrated information)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 08 November 2010 - 15 April 2011
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP - Guideline study. No gross examination of pups was performed after sacrifice.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 011
- Report date:
- 2011
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 421 (Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- yes
- Remarks:
- No gross examination of pups was performed after sacrifice
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Slovak National Accreditation Service
- Limit test:
- no
Test material
Reference
- Name:
- Unnamed
- Type:
- Constituent
- Details on test material:
- - Name of test material (as cited in study report): SP-334LM
- Physical state: solid (powder)
- Analytical purity: 99.7%
- Purity test date: 9 Jul 2010
- Lot/batch No.: 34692
- Expiration date of the lot/batch: 01 January 2012
- Stability under test conditions: stable
- Storage condition of test material: at room temperature in the dark
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Velaz Praha, Czech Republic
- Age at study initiation: adult males/females
- Weight at study initiation: mean body weight: males 205.3 g, females 197.8 g
- Housing: All animals were kept in cages with bedding (wood shavings) under standard conditions. During the pre-mating period 4 rats/sex/cage; duringthe mating period 1 manle and 1 female per cage; during the gestation period pregnant females were caged individually; during the lactation period females were caged individually together with the offspring; after the mating procedure males were returned to the original cages, 4 males per cage
- Diet: conventional laboratory diet (MP-OŠ-06, BIOFER, 06901, Snina, Slovak Republic)
- Water: drinking water, ad libitum
- Acclimation period: 12 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22±2
- Humidity (%): 45-65
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 12 October 2010 To: 12 November 2010 (males) and 11 or 12 November 2010 (females)
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- olive oil
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: The solution with the test article was prepared daily before application and administered within 2 hours. SP-334 at concentrations of 10 mg/mL, 40 mg/mL and 200 mg/mL in olive oil were prepared by mixing an accurately weighed amount of SP-334 with olive oil. The solution of SP-334 is stable up to 24 hours at laboratory temperature.
VEHICLE
- Justification for use and choice of vehicle (if other than water): SP-334 is not soluble in the water; therefore the olive oil was used as the vehicle.
- Concentration in vehicle: 1, 4 and 10% (w/v)
- Amount of vehicle (if gavage): 0.5 mL/100 g body weight
- Lot/batch no. (if required): 100 - Details on mating procedure:
- - M/F ratio per cage: 1/1
- Length of cohabitation: maximum 14 days, until proof of pregnancy
- Proof of pregnancy: vaginal plug or sperm in vaginal smear; referred to as day 0 of pregnancy
- After 6 days of unsuccessful pairing replacement of first male by another male with proven fertility
- Further matings after two unsuccessful attempts: no
- After successful mating each pregnant female was caged (how): individually - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The precision, homogeneity and stability of formulation was analysed against standard samples by HPLC. The precision and homogeneity met the requirements of 90-110% of the nominal concentration (relative SD ≤3%). The stability after 24 hours at room temperature was acceptable; as the mean values measured at 24 hours were shown to be within ±5% of the values measured at 0 hours.
- Duration of treatment / exposure:
- males: 28 days
females: up to 56 days (14 days before the mating procedure, up to 14 days during the mating process, 22–24 days during gestation, and 4 days during the lactation) - Frequency of treatment:
- Daily
- Details on study schedule:
- - Age at mating of the mated animals in the study: adults
Doses / concentrations
- Remarks:
- Doses / Concentrations:
50, 200 and 1000 mg/kg bw/d
Basis:
nominal conc.
- No. of animals per sex per dose:
- 12
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: In a subacute 28-day oral toxicity study, 12 rats/sex/group were administered 50, 200 and 1000 mg/kg bw/d of the test substance by gavage (Pels Rijken, 1998). There was no treatment-related mortality. One female administered 50 mg/kg bw/d died on day 27, most likely due to mis-dosing. Red staining of the fur was observed in females in the highest dose group. A discharge from the nose and eyes that is spread over the fur during grooming is normal in rats. The increased discharge is probably a consequence of the stress rats are subject to during the repeated dosing by gavage, and is therefore related to treatment but not to the test substance. The NOAEL was considered to be 1000 mg/kg bw/d, based on the lack of effects at the highest dose level. The same dose levels as those used in the 28-day repeated dose study were therefore selected for the reproduction/developmental screening toxicity study.
Examinations
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVAIONS: Yes
- Time schedule: daily
- Cage side observations included: mortality, clinical signs (piloerection, alopecia, dyspnoea, salivation, smooth stool, diarrhoea, tremors, spasms, hyperactivity, lethargy, cannibalism, aborts, moribund state)
DETAILED CLINICAL OBSERVATIONS: No
BODY WEIGHT: Yes
- Time schedule for examinations: animals were weighed on the first day of dosing, then weekly thereafter, and at study termination. During the gestation period, females were weighed on day 0, 7, 14, 20; within 24 hours of parturition (day 1 post-partum); and on day 4 post-partum.
FOOD CONSUMPTION AND COMPOUND INTAKE:
Food consumption was measured weekly - Litter observations:
- STANDARDISATION OF LITTERS
- Performed on day 4 postpartum: yes
PARAMETERS EXAMINED
The following parameters were examined in F1 offspring:
number and sex of pups, stillbirths, live births, postnatal mortality, presence of gross anomalies, weight, physical or behavioural abnormalities.
The litters were weighed 24 hours after the birth and on day 4 post-partum.
GROSS EXAMINATION OF DEAD PUPS: no - Postmortem examinations (parental animals):
- SACRIFICE
- Male animals: All surviving animals were sacrificed after 28 days of treatment
- Maternal animals: All surviving females were sacrificed on day 5 post-partum
GROSS NECROPSY
- A gross necropsy, consisted of external and internal macroscopic examination of for abnormalities or pathological changes, was performed on all animals that died during the study period and the animals sacrificed at the end of the study
HISTOPATHOLOGY / ORGAN WEIGHTS
A histopathologic examination was performed on the animals in the control and highest dose group. The liver, kidneys (target organs), testes, epididymes, uterus, and ovaries were weighed. The samples from the above-mentioned organs including the prostate (including coagulating glands) and mammary gland were processed for microscopic examination. All tissue samples were fixed in formaldehyde. - Postmortem examinations (offspring):
- SACRIFICE
- The surviving offspring were sacrificed on day 5 post-partum - Statistics:
- The results (body weight of animals, litters, and organs, food consumption, number of corpora lutea and implantation sites) were statistically evaluated by the statistical programme Statgraphics. The statistical evaluated was made separately for the males, females, and litters. For the identification of homogeneity of the groups Bartlett’s test was used. In the case of homogeneitya One-Way Analysis of variance with consecutive Multiple-Ranges tests was used. In the case of non-homogeneity and for the length of pregnancy Kruskal-Wallis One Way Analysis by Ranks was applied.
- Reproductive indices:
- The following reproductive indices were calculated: fertility index and gestation (pregnancy) index
- Offspring viability indices:
- The following indices were calculated: live birth index and viability (survival) index
Live birth index = (number of live offspring / number of offspring delivered) x 100
Viability (survival) index = (number of live offspring at lactation day 4/number of live offspring delivered) x 100
Results and discussion
Results: P0 (first parental generation)
General toxicity (P0)
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- alopecia
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- no effects observed
- Other effects:
- no effects observed
Reproductive function / performance (P0)
- Reproductive function: oestrous cycle:
- no effects observed
- Reproductive function: sperm measures:
- not examined
- Reproductive performance:
- effects observed, treatment-related
- Description (incidence and severity):
- gestation period
Details on results (P0)
Mortality: 0, 2, 1 and 0 in the female control, 50, 200 and 1000 mg/kg bw/d groups, respectively. The animals had inflammation of the endometrium, which is not considered to be test substance-related. No males died during the study period.
Alopecia was noted in several females on one or several days in all groups during day 27-44; in total in 2, 1, 3 and 1 females in the control, 50, 200 and 1000 mg/kg bw/d groups, respectively. This was not considered to be a treatment-related occurrence.
BODY WEIGHT AND FOOD CONSUMPTION (PARENTAL ANIMALS)
There was no statistically significant difference in body weight or food consumption between the control group and treament groups.
REPRODUCTIVE PERFORMANCE (PARENTAL ANIMALS)
A statistically significant increase in gestation period (≥23 days) was noted in the 200 and 1000 mg/kg bw/d groups (see table 1). However, the number was highest in the 200 mg/kg bw/d group (8 females) and the number in the 1000 mg/kg bw/d group was the same as for the control group (4 females). As the results are not dose-related and there are no other effects on reproductive parameters, this is not considered to be a treatment-related effect, despite a statistical significance. There was no statistically significant difference in reproductive performance, measured as pregnancy rate (fertility index), gestation index, live birth index and viability index, between the control group and treament groups (see table 1). There was a reduction in the number of implants and number of live pups (not statistically significant), showing a seemingly dose-related trend. However, historical data (see table 2) indicate that the results in this study fall within the expected range and are therefore not related to treatment with the test substance.
ORGAN WEIGHTS (PARENTAL ANIMALS)
The relative liver weight of males administered 1000 mg/kg bw/d was statistically significantly increased, compared to the male control group. An increase in liver weight is frequently observed in repeated dose studies, as the liver is enlarged due to the increased metabolising activity caused by the high intake the test substance. This effect is considered to be an adaptation, rather than an adverse effect (see table 3).
GROSS PATHOLOGY (PARENTAL ANIMALS)
There were no treatment-related effects on gross pathology.
HISTOPATHOLOGY (PARENTAL ANIMALS)
There were no treatment-related effect on histopathology.
Effect levels (P0)
open allclose all
- Dose descriptor:
- NOAEL
- Remarks:
- reproduction
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No effects observed up to the highest dose level
- Dose descriptor:
- NOAEL
- Remarks:
- fertility
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No effects observed up to the highest dose level
- Dose descriptor:
- NOAEL
- Remarks:
- systemic
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No effects observed up to the highest dose level
Results: F1 generation
General toxicity (F1)
- Clinical signs:
- no effects observed
- Mortality / viability:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Sexual maturation:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- not examined
- Histopathological findings:
- not examined
Details on results (F1)
A slight reduction in the viability on day 4 was observed (not statistically significant), showing a seemingly dose-related trend. However, historical data (see table 2) indicate that the results in this study fall within the expected range and are therefore not related to treatment with the test substance.
CLINICAL SIGNS (OFFSPRING)
No clinical signs of toxicity were observed.
BODY WEIGHT (OFFSPRING)
There were no treatment-related effects on body weight.
Overall reproductive toxicity
- Reproductive effects observed:
- not specified
Any other information on results incl. tables
Table 1: results of mating procedure, pregnancy parameters and offspring viability:
Observations |
Values |
|||
Dosage |
Control group |
Low dose group |
Medium dose group |
High dose group |
Pairs started (N) |
12 |
12 |
12 |
12 |
Females showing evidence of copulation (N) |
12 |
12 |
12 |
11 |
Females achieving pregnancy (N) |
10 |
11 |
12 |
9 |
Conceiving days 1 – 5 (N) |
12 |
12 |
11 |
11 |
Conceiving days 6 – 14(N) |
0 |
0 |
1 |
0 |
Pregnancy ≤ 21 days (N) |
0 |
0 |
0 |
0 |
Pregnancy = 22 days (N) |
6 |
6 |
3 |
4 |
Pregnancy ≥ 23 days (N) |
4 |
5 |
8* |
4* |
Dams with live young born (N) |
10 |
9 |
10 |
7 |
Dams with live young at day 4 pp (N) |
8 |
8 |
8 |
7 |
Corpora lutea / dam (mean) |
15 |
14 |
14 |
11 |
Implants / dam (mean) |
13 |
11 |
10 |
7 |
Live pups / dam at birth (mean) |
11 |
8 |
9 |
7 |
Live pups / dam at day 4 (mean) |
12 |
9 |
8 |
7 |
Sex ratio (m / f) at day 4 (mean) |
5/7 |
4/5 |
4/5 |
4/4 |
Litter weight at birth (mean) |
56.50 |
51.67 |
50.00 |
46.43 |
Litter weight at day 4 (mean) |
81.88 |
75.63 |
65.00 |
65.71 |
ABNORMAL PUPS |
||||
Dams with 0 |
0 |
0 |
0 |
0 |
Dams with 1 |
0 |
0 |
0 |
0 |
Dams with ≥ 2 |
0 |
0 |
0 |
0 |
LOSS OF OFFSPRING |
||||
Pre-implantation (corpora lutea minus implantations) |
||||
Females with 0 |
6 |
2 |
2 |
3 |
Females with 1 |
1 |
3 |
1 |
0 |
Females wits 2 |
1 |
1 |
2 |
1 |
Females with ≥ 3 |
2 |
5 |
7 |
5 |
Pre-natal / post-implantations (implantation minus live birth) |
||||
Females with 0 |
0 |
5 |
3 |
2 |
Females with 1 |
4 |
2 |
5 |
6 |
Females with 2 |
3 |
1 |
1 |
0 |
Females with ≥ 3 |
3 |
3 |
3 |
1 |
Post-natal (live births minus alive at post-natal day 4) |
||||
Females with 0 |
6 |
10 |
9 |
9 |
Females with 1 |
3 |
1 |
1 |
0 |
Females with 2 |
0 |
0 |
0 |
0 |
Females with ≥ 3 |
1 |
0 |
2 |
0 |
* No 28, 46 - exact day of birth unknown
Table 2: Historical data from control groups treated with olive oil (vehicle) only
Parameter |
Range |
Number of implants/dam |
5-16 |
Live pups/dam at birth |
3-15 |
Pup survival to day 4 |
3-15 |
Table 3: Relative liver weight
Dose (mg/kg bw/d) |
Control |
50 |
200 |
1000 |
Relative liver weight, males (%) |
3.81±0.21 |
3.90±0.24 |
3.85±0.48 |
4.17±0.18* |
Relative liver weight, females (%) |
5.09±0.72 |
4.63±0.59 |
5.27±0.58 |
5.82±0.77 |
* statistically significant difference compared to control
Applicant's summary and conclusion
- Conclusions:
- CLP: not classified
DSD: not classified - Executive summary:
In a screening study performed according to OECD 421, the potential adverse effect of SP-334 on reproduction and developmental parameters in rats was assessed.
12 Wistar rats/dose/sex were administered 0, 50, 200 and 1000 mg/kg bw/d; males for 28 days during the pre-mating and mating periods, and females for up to 56 days during the pre-mating, mating, and gestation period and during lactation until day 4. The control group received the vehicle (olive oil). A fixed application volume of 0.5 mL/100 g body weight was administered by gavage.
There were 3 unscheduled cases of mortality in female dose groups; 2/12 in the 50 mg/kg bw/d group and 1/12 in the 1000 mg/kg bw/d group, respectively. The animals had inflammation of the endometrium, which is not considered to be test substance-related. No males died during the study period. Alopecia was noted in several females on one or several days in all groups during day 27-44; in total in 2, 1, 3 and 1 female in the control, 50, 200 and 1000 mg/kg bw/d groups, respectively. This is a normal occurrence in rats during repeated dose studies and is not considered to be treatment-related.The relative liver weight of males administered 1000 mg/kg bw/d was statistically significantly increased, compared to the male control group. The liver weight was 3.81, 3.90, 3.85 and, in the control, 50, 200 and 1000 mg/kg bw/d dose groups, respectively. An increase in liver weight is frequently observed in repeated dose studies, as the liver is enlarged due to the increased metabolising activity caused by the high intake the test substance. This effect is considered to be an adaptation, rather than an adverse effect. No treatment-related findings were noted during gross necropsy and histopathological examination.
A statistically significant increase in gestation period (≥23 days) was noted in the 200 and 1000 mg/kg bw/d groups. However, the number was highest in the 200 mg/kg bw/d group (8 females) and the number in the 1000 mg/kg bw/d group was the same as for the control group (4 females). As the results are not dose-related and there are no other effects on reproductive parameters, this is not considered to be a treatment-related effect, despite a statistical significance. There was no statistically significant difference in other reproductive parameters between the control group and treatment groups.
The NOAEL (No-Observed-Adverse-Effect Level) for reproduction in males and females is considered to be 1000 mg/kg bw/d, as no effects were observed up to and including the highest dose level.
The NOAEL for systemic toxicity is also considered to be 1000 mg/kg bw/d for males and females, as no effects were noted up to and including the highest dose level.
In the offspring (F1 -generation) a slight reduction in the viability on day 4 was observed (not statistically significant), showing a seemingly dose-related trend. However, historical data indicate that the results in this study fall within the expected range and are therefore not related to treatment with the test substance. No clinical signs of toxicity were observed in the offspring and there were no effects on the body weight.
No treatment-related effects were observed up to and including the highest dose level, therefore the NOAEL for developmental effects is considered to be 1000 mg/kg bw/d.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.